POLYENDOCRINE METABOLIC SYNDROME (PMOS): A CONCISE REVIEW OF PATHOPHYSIOLOGY, MANAGEMENT, AND AYURVEDIC PERSPECTIVE

Author

Dr. Ratnika Tiwari , Dr. Ankita Thakur, Dr. Reetu Pandey


Abstract

 Background: The condition historically termed polycystic ovary syndrome (PCOS) has undergone a crucial paradigm shift and is now recognized as Polyendocrine Metabolic Syndrome (PMOS).1 Ovarian 'cysts' represent secondary manifestations of systemic insulin resistance, hyperandrogenism, and chronic inflammation rather than a primary gynaecological pathology.1,2

Objective: To review the rationale behind the update from PCOS to PMOS, synthesize its pathophysiology, present modern management strategies, and explore Ayurvedic conceptual correlates1-3.

Methods: A concise review synthesizing academic literature, consensus guidelines (including ESHRE/ASRM updates), and classical Ayurvedic texts1-5.

Results: PMOS involves hypothalamic-pituitary-ovarian axis dysregulation, hyperinsulinemia, elevated LH:FSH ratios (>2:1 or >3:1), central obesity, and follicular arrest1,3. Modern therapeutics combine lifestyle interventions, COCPs, metformin, GLP-1 agonists, and letrozole2,4. Ayurveda conceptualizes PMOS via Pushpaghni Jatharini, Artavakshaya, Beejagranthi, and Kapha-Vata Srotorodha5-7.

Conclusion: Updating the nomenclature to Polyendocrine Metabolic Syndrome (PMOS) emphasizes early screening for type 2 diabetes and metabolic risk while unifying modern metabolic therapy with Ayurvedic holistic protocols1,2,5.



Keywords

Polyendocrine Metabolic Syndrome, PMOS, PCOS, Hyperinsulinemia, Artavakshaya, Pushpaghni Jatharini, Ayurveda.



Full Text:

Download Paper PDF


References


  1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
  2. Teede HJ, Tay CT, Laven J, Dokter E, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43-G64.
  3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.
  4. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-129.
  5. Sharma PV, editor. Charaka Samhita of Agnivesa (Text with English Translation). Varanasi: Chaukhambha Orientalia; 2004.
  6. Tiwari PV, editor. Kasyapa Samhita or Vriddhajivakiya Tantra. Varanasi: Chaukhambha Visvabharati; 2002.
  7. Murthy KR, translator. Sushruta Samhita (Text with English Translation). Varanasi: Chaukhambha Orientalia; 2008.
  8. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and PCOS Society. Hum Reprod Update. 2014;20(3):334-352.
  9. Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. Liraglutide reduces visceral fat and weight in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2015;172(1):41-48.
  10. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257.

Share your valuable work from Social Media Buttons